Summary of European Medicines Agency Assessment Report on Sambucus nigra. (Elderberry)
May modulate activity of immune cells.
Data is not conclusive.
Inhibitory effect on influenza virus strains studied.
Clear results in lab studies
Mixed results in studies on human cells*.
High concentrations of chemicals known for antioxidant properties.
Mixed study results on effects of stress in cells* in vitro.
Antibacterial activity found against H. Pylori and MRSA.
Lectins are sugar binding proteins
Lectin activities have been established by studies
Applications for lectin activities (diabetes) has been studied. Mixed results.
High-risk of toxicity with ripe fruit
No concerns with cooked or heat treated products.
Avoid bark of the plant. (toxic)
The proportion of active substances in elderberry that enter the circulation after being consumed is low across all preparations.
Little data is available for dosing, likely due to low bioavailability.
Adverse events in a few individuals have been reported.
Abdominal pain, Edema in Legs, Decreased INR (increased blood clotting)
*For the purposes of this report, Non clinical data represents pharmacodynamics, and toxicology from laboratory (in-vitro) experiments. Clinical data represents pharmacokinetic, bioavailability, and clinical trial data. Safety data represents information on clinical exposures.